Washout Window Under Enrollment Pressure
A phase II rheumatoid arthritis trial is screening Mr. D, a 57-year-old man with a 6-year history of seropositive RA. Inclusion requires inadequate response to methotrexate; exclusion includes strong CYP3A4 inhibitors within 14 days before the first dose of study drug. Mr. D completed a 7-day course of clarithromycin for sinusitis; his last dose was 6 days ago. His screening labs are otherwise acceptable: eGFR 47 mL/min/1.73 m² (protocol excludes <45), ALT 28 U/L, and negative hepatitis B and C. The first-dose visit is scheduled tomorrow, and the site's screening window closes in 3 days. The sponsor's enrollment team emailed that the cohort is two participants short and asked sites to 'avoid unnecessary screen failures.' The PI says, 'Six days is close enough; the exposure difference is probably minimal. Enroll him and note it as a deviation.' Mr. D has arranged childcare and took time off work for tomorrow's visit.
1. What should the coordinator do about tomorrow's first-dose visit, and what is the protocol-based rationale?
Read the worked answer
The coordinator should not permit the first dose tomorrow. Clarithromycin is a strong CYP3A4 inhibitor, and the protocol requires it to be stopped for 14 days before the first study-drug dose. Counting the last dose as day 0, tomorrow is only day 7; the earliest permissible first dose is day 15. 'Probably minimal' exposure is not an eligibility determination the site may make. A protocol deviation that enrolls an ineligible subject can increase toxicity risk, invalidate pharmacokinetic and safety data, and trigger a finding at audit. The coordinator should place the first-dose visit on hold, notify the PI and the sponsor medical monitor in writing, and ask whether the protocol permits a later first dose within the screening window or requires a screen failure and re-screening. The coordinator should not alter the screening date, dispense investigational product, or record eligibility as met. If the PI still directs enrollment, the coordinator should use the site chain of command and report the concern to the monitor and IRB per policy; the coordinator's obligation is subject safety and accurate records.
2. The PI insists on enrolling Mr. D and documenting a deviation. How should the coordinator respond and document this?
Read the worked answer
The coordinator should respond factually, not confrontationally: 'I cannot enroll an ineligible participant or document a deviation as a workaround. The protocol defines the washout, and the IRB approved that criterion.' Document the PI's instruction and the coordinator's response in a non-inflammatory file note with date and time. Notify the sponsor monitor and medical monitor promptly; they can clarify any protocol allowance in writing. Do not backdate, do not create a source note saying the last clarithromycin dose was earlier, and do not ask the subject to misreport. If the PI insists on proceeding, escalate to the IRB, the institution's research compliance office, or the human research protections office. If enrollment occurs despite the objection, report it immediately as a protocol deviation or unanticipated problem, because subject safety and data integrity are affected. Use established reporting channels and keep the subject's interests primary.
3. What should the coordinator tell Mr. D, and what follow-up options are appropriate?
Read the worked answer
Tell Mr. D that the start must be delayed because of the clarithromycin washout, without blaming him or disclosing sponsor pressure. Give a clear earliest date (day 15 after the last dose) and check whether the screening window and visit schedule can accommodate it. If the protocol allows re-screening, offer that option and explain what it involves; if not, document a screen failure. Do not promise enrollment or imply the criterion can be waived. Explore whether he has another prohibited medication and provide the list. Acknowledge his work and childcare arrangements and offer the next available compliant appointment. Document the discussion, his questions, and the plan in the source record. If he declines re-screening, thank him and close out screening per protocol. The key is to preserve trust while refusing to misrepresent eligibility.